Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROUGH-2 phase 2 study of MAR002 in acromegaly
CTR20264171Phase 2Active
- Sponsor
- Marea Therapeutics
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MAR002 in acromegaly (4 arms), sponsored by Marea Therapeutics. Primary endpoints: Treatment-emergent adverse events, serious adverse events, and laboratory safety outcomes through end of study and Percent change from baseline in serum IGF-1. Started Nov 2026; status: active.
02
Drugs
MAR002
03
Conditions
acromegaly
Beyond the preview
Go deeper on CTR20264171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264171.